New online melanoma risk calculators critical to saving lives

New online melanoma risk calculators critical to saving lives

28 August 2020

Clinicians and their patients now have access to a series of online calculators which will assist in prevention, early detection and optimum treatment of melanoma, ultimately saving lives.

Developed by researchers at Melanoma Institute Australia and based on published risk prediction models, the three web-based calculators are housed on a new Melanoma Risk website launched today.

They predict a person’s risk of developing their first melanoma; their risk of developing a second or subsequent primary melanoma; and their risk of a primary melanoma having spread to nearby lymph nodes.

MIA Co-Medical Directors, Professor Richard Scolyer and Professor Georgina Long AO, said the risk calculators were the latest in the growing arsenal of early detection tools and ground-breaking treatments which they believed would culminate in achieving zero deaths from melanoma this decade.

‘Awareness, prevention, early detection and optimum treatment are key when it comes to tackling melanoma and saving lives from this disease,’ said Professor Richard Scolyer.

‘The online risk calculators are designed to inform discussions between clinicians and patients; two promote prevention and tailored skin surveillance programs for early detection and the third facilitates specialised treatment plans according to the specific patient’s risk,’ he said.

‘The development of these wonderful online tools is testament to the great work of many of our researchers and clinicians at MIA and will move us closer to reaching zero deaths from melanoma,’ added Professor Georgina Long AO.

Currently, Australia has one of the highest melanoma rates in the world with one person diagnosed every 30 minutes and one person dying every five hours from the disease.

The launch of the calculators comes amidst concerns the COVID-19 pandemic may have caused Australians to delay seeking checkups for melanoma and other cancers where early detection is vital for optimum outcomes.

Two of the calculators use patient information such as age, skin type, family history and sun exposure history to calculate individual lifetime risk of a person developing either their initial primary melanoma or a subsequent one. This information then guides discussions between the patient and the clinician about appropriate sun protection behaviours as well as the optimum schedule of skin checks to ensure early detection.

The third calculator predicts risk of disease having spread from a primary melanoma to nearby lymph nodes, and potentially metastasising to other vital organs. It takes into account additional clinical information about the primary melanoma as well as a patient’s age.

This calculator enables those deemed to be at low risk of disease spread to safely forgo surgery for a sentinel node biopsy. Conversely, it also detects patients at higher risk of disease spread, increasing potential for earlier identification of lymph node spread and activation of optimum treatment.

‘This calculator predicting risk of disease spread is particularly of benefit to older patients who are less likely to have melanoma spread to their lymph nodes, but who are at increased risk of complications that can come from additional surgery and general anaesthesia,’ added Professor Long AO.

The three web-based calculators can be accessed at www.melanomarisk.org.au

Updated Clinical Guidelines for Melanoma
25 May 2018

Updated Clinical Guidelines for Melanoma

Melanoma patients across Australia will benefit from the release of updated clinical care guidelines.

Melanoma and Marital Status: A Study
11 May 2018

Melanoma and Marital Status: A Study

An American study has discovered a link between early detection and marital status in melanoma diagnosis. 

A weekend in Paris talking all things pathology...
02 May 2018

A weekend in Paris talking all things pathology...

An international course on melanoma pathology in Paris, France co-directed by Professor Richard Scolyer took place over the weekend.

Our own 'Australian Story'
30 Apr 2018

Our own 'Australian Story'

Professor Richard Scolyer highlights the difficulties of diagnosis following the Australian Story feature program on Emma Betts. 

Cancer Australia releases 'stage at diagnosis' data for top five incidence cancers – including melanoma
27 Apr 2018

Cancer Australia releases 'stage at diagnosis' data for top five incidence cancers – including melanoma

For the first time in Australia, national data has been released on cancer stage at diagnosis. This data explores the top five incidence cancers – female breast cancer, colorectal, lung, prostate cancers and melanoma.

The inspiring story of Emma Betts premieres on Australian Story
16 Apr 2018

The inspiring story of Emma Betts premieres on Australian Story

'Dear Emma' - a tribute to the life and times of a young woman determined to raise awareness about melanoma. 

Toyota helps tackle Australia's national cancer - melanoma
09 Apr 2018

Toyota helps tackle Australia's national cancer - melanoma

Carole Renouf, CEO for MIA thanks Toyota for helping fuel ongoing melanoma research.

Tackling the Kokoda Trail for melanoma
06 Apr 2018

Tackling the Kokoda Trail for melanoma

Fraser Dykes tackled the Kokoda Trail on an eight day trek in memory of his friend Mark 'Bod' Boddison.

Professor Richard Scolyer presents at world's largest annual meeting of pathologists
29 Mar 2018

Professor Richard Scolyer presents at world's largest annual meeting of pathologists

Harvard’s Clinical Professor Martin Mihm and MIA’s Conjoint Medical Director Professor Richard Scoyler delivered a series of lectures on melanoma pathology in Vancouver, British Colombia this week at the world’s biggest annual pathology meeting.

Congratulations to Kaye Oakley
29 Mar 2018

Congratulations to Kaye Oakley

A round of applause for a well deserved win.

Farewell from Carole Renouf, CEO of Melanoma Institute Australia
26 Mar 2018

Farewell from Carole Renouf, CEO of Melanoma Institute Australia

A message from our CEO, Carole Renouf

Marching in the twilight
26 Mar 2018

Marching in the twilight

Piction, Brisbane, Bahturst and Port Macquarie march to end melanoma. 

Researchers uncover treatment sequence for advanced melanoma patients
23 Mar 2018

Researchers uncover treatment sequence for advanced melanoma patients

Australian researchers have greater clarity on the best course of treatment for patients with advanced melanoma which has spread to the brain.

An unsung hero of melanoma care for nearly 30 years
22 Mar 2018

An unsung hero of melanoma care for nearly 30 years

Melanoma treatment has come a long way in recent times, and the role that nurses play caring for melanoma patients has changed dramatically too.

Sharing our research on melanoma surgery
21 Mar 2018

Sharing our research on melanoma surgery

MIA is sharing it's research with the global surgical oncology community this week at the Society of Surgical Oncology Annual Cancer Symposium.

14 Melanoma Marches down, 7 to go!
19 Mar 2018

14 Melanoma Marches down, 7 to go!

It was a massive weekend of Melanoma Marches with six Marches in: Bendigo, Canberra, Manly, Newcastle, Bunbury and Adelaide.

Melanoma March keeps marching
14 Mar 2018

Melanoma March keeps marching

Weekend two hit the ground marching with Melanoma Marches in Wollongong, Townsville, Mandurah and Western Sydney.

Melanoma March kicks off for 2018
08 Mar 2018

Melanoma March kicks off for 2018

Melanoma Institute Australia's annual fundraising initiative is all systems go!

Calls for urgent crackdown on illegal backyard solariums
07 Mar 2018

Calls for urgent crackdown on illegal backyard solariums

The reported proliferation of illegal commercial solariums is costing lives and requires urgent government intervention.

15-year-old melanoma survivor Toby Rayner will lead Mount Gambier's march against melanoma
28 Feb 2018

15-year-old melanoma survivor Toby Rayner will lead Mount Gambier's march against melanoma

15-year-old melanoma survivor Toby Rayner will lead Mount Gambier’s march against melanoma Julie-Ann Sams knows all too well that melanoma doesn’t discriminate.